Compare ESP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | ENTX |
|---|---|---|
| Founded | 1928 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 142.0M |
| IPO Year | N/A | 2018 |
| Metric | ESP | ENTX |
|---|---|---|
| Price | $44.74 | $2.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 15.8K | ★ 76.2K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $42,600,530.00 | $124,000.00 |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $13.74 | ★ N/A |
| Revenue Growth | 4.90 | ★ 25.25 |
| 52 Week Low | $24.85 | $1.50 |
| 52 Week High | $55.00 | $3.22 |
| Indicator | ESP | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 71.97 | 36.62 |
| Support Level | $41.30 | $2.07 |
| Resistance Level | $44.30 | $2.27 |
| Average True Range (ATR) | 1.66 | 0.17 |
| MACD | 0.54 | -0.02 |
| Stochastic Oscillator | 97.46 | 1.47 |
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.